JPH10298088A - Composition for curing cold syndrome improved in feeling when taking the same - Google Patents
Composition for curing cold syndrome improved in feeling when taking the sameInfo
- Publication number
- JPH10298088A JPH10298088A JP9107849A JP10784997A JPH10298088A JP H10298088 A JPH10298088 A JP H10298088A JP 9107849 A JP9107849 A JP 9107849A JP 10784997 A JP10784997 A JP 10784997A JP H10298088 A JPH10298088 A JP H10298088A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- echinacea
- cold syndrome
- feeling
- taking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 244000133098 Echinacea angustifolia Species 0.000 claims abstract description 28
- 235000014134 echinacea Nutrition 0.000 claims abstract description 28
- 239000003907 antipyretic analgesic agent Substances 0.000 claims abstract description 24
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960005489 paracetamol Drugs 0.000 claims abstract description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 8
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002189 propyphenazone Drugs 0.000 claims abstract description 6
- 238000013329 compounding Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 5
- 239000000730 antalgic agent Substances 0.000 abstract description 3
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 abstract description 2
- 229960000514 ethenzamide Drugs 0.000 abstract 1
- 230000001047 pyretic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 21
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 11
- -1 Isotipendyl Chemical compound 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- 229960001948 caffeine Drugs 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229960003556 aminophylline Drugs 0.000 description 4
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 229940124584 antitussives Drugs 0.000 description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 229960002146 guaifenesin Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 3
- 229940069428 antacid Drugs 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229940066493 expectorants Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000521877 Echinacea paradoxa Species 0.000 description 2
- 241000313460 Echinacea sanguinea Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960000456 carbinoxamine maleate Drugs 0.000 description 2
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229940124579 cold medicine Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- JTUQXGZRVLWBCR-UHFFFAOYSA-N 1-[1-[2-(phenylmethyl)phenoxy]propan-2-yl]piperidine Chemical compound C1CCCCN1C(C)COC1=CC=CC=C1CC1=CC=CC=C1 JTUQXGZRVLWBCR-UHFFFAOYSA-N 0.000 description 1
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- NMJHYEAUFBCOLQ-UHFFFAOYSA-N 3,4-diphenyl-2h-pyran-2-amine Chemical compound NC1OC=CC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 NMJHYEAUFBCOLQ-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 241000567769 Isurus oxyrinchus Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960003870 bromhexine Drugs 0.000 description 1
- OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229960004472 clofedanol Drugs 0.000 description 1
- WRCHFMBCVFFYEQ-UHFFFAOYSA-N clofedanol Chemical compound C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 WRCHFMBCVFFYEQ-UHFFFAOYSA-N 0.000 description 1
- 229960002544 cloperastine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229940031005 ethyl cysteine Drugs 0.000 description 1
- PFAXACNYGZVKMX-UHFFFAOYSA-N fenethazine Chemical compound C1=CC=C2N(CCN(C)C)C3=CC=CC=C3SC2=C1 PFAXACNYGZVKMX-UHFFFAOYSA-N 0.000 description 1
- 229950007454 fenethazine Drugs 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- OATDVDIMNNZTEY-DAXLTYESSA-N flutropium Chemical compound C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 OATDVDIMNNZTEY-DAXLTYESSA-N 0.000 description 1
- 229950005583 flutropium Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- POOYFSLWYLDQMD-UHFFFAOYSA-N heptacalcium;zinc Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Zn+2] POOYFSLWYLDQMD-UHFFFAOYSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 229960003436 pentoxyverine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229950000112 serrapeptase Drugs 0.000 description 1
- 108010038132 serratiopeptidase Proteins 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- JWIXXNLOKOAAQT-UHFFFAOYSA-N tipepidine Chemical compound C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 JWIXXNLOKOAAQT-UHFFFAOYSA-N 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、新規な風邪症候群
治療用組成物に関する。詳しくは、エキナケア及び解熱
鎮痛薬を配合してなる服用感が改善された風邪症候群治
療用組成物である。TECHNICAL FIELD The present invention relates to a novel composition for treating cold syndrome. Specifically, the present invention is a composition for treating a cold syndrome, comprising an echinacea and an antipyretic analgesic, and having an improved feeling of taking.
【0002】[0002]
【従来の技術】風邪症候群は、主として上気道に起こる
急性カタル性炎症の総称である。病因の80〜90%は
ウイルスであるが、風邪ウイルスはその種類が多いうえ
変異を起こし易い。したがって、未だ風邪ウイルスに対
する有力なワクチンや抗ウイルス剤は開発されていない
のが現状であり、風邪症候群に対する薬物治療は対症療
法が中心となっている。かかる風邪症候群の治療剤にお
いては、風邪の代表的症候群である発熱、頭痛、筋肉
痛、咽頭炎、悪寒等の軽減を目的に、解熱鎮痛薬が使用
されることが多い。2. Description of the Related Art The cold syndrome is a general term for acute catarrhal inflammation mainly occurring in the upper respiratory tract. Eighty to 90% of the etiologies are viruses, but cold viruses are numerous and susceptible to mutation. Therefore, at present, no effective vaccine or antiviral agent against the cold virus has been developed, and pharmacotherapy for the cold syndrome is mainly symptomatic treatment. Antipyretic analgesics are often used in the treatment of such cold syndrome for the purpose of reducing fever, headache, myalgia, pharyngitis, chills and the like which are typical syndromes of cold.
【0003】しかし、かかる解熱鎮痛薬は服用に際し苦
味を伴うため、風邪症候群治療剤はその服用感の悪さ
が、とくにコンプライアンスの観点から課題となってい
る。[0003] However, such antipyretic analgesics have a bitter taste when taken, so that the cold remedy has a problem of poor feeling of taking, particularly from the viewpoint of compliance.
【0004】一方、エキナケア(Echinacea)
は、北アメリカ大陸原産の草本類の一種であり、免疫賦
活薬として、主にヨーロッパにおいて風邪の予防および
風邪症状の改善の目的で粉末剤、固形剤、エキス、茶等
の形態で繁用されている生薬である。On the other hand, Echinacea
Is a kind of herb native to the North American continent and is commonly used as an immunostimulant in the form of powders, solids, extracts, tea, etc., mainly in Europe for the purpose of preventing colds and improving cold symptoms. There is a crude drug.
【0005】しかし、解熱鎮痛薬を含む風邪症候群治療
剤に服用感の改善を目的としてエキナケアを配合した処
方は知られていない。[0005] However, there is no known prescription in which echinacea is mixed with a remedy for a cold syndrome containing an antipyretic analgesic for the purpose of improving the feeling of taking.
【0006】[0006]
【発明が解決しようとする課題】本発明は上記従来技術
の有する問題点に鑑みなされたものであり、その目的と
するところは、有効量の解熱鎮痛剤を含有しつつも服用
感に優れ、コンプライアンスが改善された風邪症候群治
療用組成物を提供することにある。DISCLOSURE OF THE INVENTION The present invention has been made in view of the above-mentioned problems of the prior art, and has as its object the purpose of containing an effective amount of an antipyretic analgesic and excellent in taking feeling. An object of the present invention is to provide a composition for treating a cold syndrome with improved compliance.
【0007】[0007]
【課題を解決するための手段】本発明者らは、上記課題
を解決すべく風症候群の対症療法剤の処方について鋭意
研究を重ねた結果、解熱鎮痛薬を含有する風邪症候群治
療剤にエキナケアを配合することにより、服用感が著し
く改善されることを見いだし本発明を完成した。Means for Solving the Problems The present inventors have conducted intensive studies on the prescription of a symptomatic treatment for wind syndrome in order to solve the above-mentioned problems. As a result, the present inventors have applied Echinacea to a treatment for cold syndrome containing an antipyretic analgesic. The inventor has found that the blending significantly improves the feeling of taking and completed the present invention.
【0008】すなわち、本発明はエキナケア及び解熱鎮
痛薬を配合してなる風邪症候群治療用組成物である。[0008] That is, the present invention is a composition for treating a cold syndrome comprising an echinacea and an antipyretic analgesic.
【0009】本発明はまた、配合比がエキナケア1重量
部に対して解熱鎮痛薬0.1〜50重量部である前記風
邪症候群治療用組成物である。The present invention also provides the composition for treating cold syndrome, wherein the compounding ratio is 0.1 to 50 parts by weight of the antipyretic analgesic to 1 part by weight of echinacea.
【0010】本発明はさらに、前記解熱鎮痛薬はアセト
アミノフェン、イブプロフェン、エテンザミドおよびイ
ソプロピルアンチピリンからなる群より選ばれた少なく
とも1種である前記風邪症候群治療用組成物である。The present invention further provides the composition for treating a cold syndrome, wherein the antipyretic analgesic is at least one selected from the group consisting of acetaminophen, ibuprofen, etensamide and isopropylantipyrine.
【0011】[0011]
【発明の実施の形態】本発明の風邪症候群治療用組成物
に用いられるエキナケアとは、植物エキナケア=プルプ
レア(Echinacea purpurea)、エキ
ナケア=アングスティフォリア(Echinacea
angustifolia)、エキナケア=パリダ(E
chinacea pallida)、エキナケア=パ
ラドクサ(Echinacea paradoxa)、
エキナケア=テネッセエンシス(Echinacea
tennesseensis)、エキナケア=サンギネ
ア(Echinacea sanguinea)、エキ
ナケア=シムラータ(Echinacea simul
ata)およびエキナケア=アトロルベンス(Echi
nacea atrorubens)ならびにこれらの
類縁生薬から抽出されるエキスもしくは原生薬末または
これらの一成分を単離したものをいい、これらの単独ま
たは2種以上を使用することができる。BEST MODE FOR CARRYING OUT THE INVENTION Echinacea used in the composition for treating a cold syndrome of the present invention includes plant echinacea purpurea, and echinacea angstifolia.
angustifolia), Echinacea-Parida (E
chinacea pallida), Echinacea paradoxa (Echinacea paradoxa),
Echinacea-Echinacea
tennesseeensis), Echinacea sanguinea (Echinacea sanguinea), Echinacea-simurata (Echinacea simul)
ata) and Echinacea-Atrolbens (Echi
extract or a crude drug powder extracted from these related crude drugs or an isolated form of one of these components, and these can be used alone or in combination of two or more.
【0012】前記エキナケアはヨーロッパハーブの一つ
であって特にドイツで繁用されており、ドイツ(Ana
sco社、Madaus社、Nattermann社、
Schaper&Bruemmer社等)からの入手が
一般的とされている。[0012] The echinacea is one of the European herbs, which is widely used especially in Germany.
sco, Madaus, Nattermann,
It is generally obtained from Schaper & Bruemmer.
【0013】本発明の風邪症候群治療用組成物に用いら
れる解熱鎮痛薬としては、アセトアミノフェン、アスピ
リン、エテンザミド、サザピリン、サリチルアミド、ス
ルピリン、インドメタシン、ジクロフェナクナトリウ
ム、イブプロフェン、ケトプロフェン、メフェナム酸、
フルフェナム酸アルミニウム、エピリゾール、塩酸チア
ラミド、塩酸チノリジン、トルメチンナトリウム、プラ
ノプロフェン、フェノプロフェンカルシウム、イソプロ
ピルアンチピリン等が挙げられ、これらの単独または2
種以上を使用することができる。これらの中ではアセト
アミノフェン、イブプロフェン、エテンザミドおよびイ
ソプロピルアンチピリンを用いた場合、特に服用感の改
善効果が大きい。The antipyretic analgesic used in the composition for treating a cold syndrome of the present invention includes acetaminophen, aspirin, etensamide, sazapyrine, salicylamide, sulpyrine, indomethacin, diclofenac sodium, ibuprofen, ketoprofen, mefenamic acid,
Aluminum flufenamic acid, epilizol, tiaramid hydrochloride, tinolizine hydrochloride, tolmetin sodium, pranoprofen, fenoprofen calcium, isopropylantipyrine and the like.
More than one species can be used. Among them, when acetaminophen, ibuprofen, etensamide and isopropylantipyrine are used, the effect of improving the feeling of taking is particularly large.
【0014】本発明の風邪症候群治療用組成物を風邪症
候群の治療剤とするためには、エキナケア及び解熱鎮痛
薬を配合する他に必要に応じて、抗ヒスタミン薬、消炎
酵素薬、気管支拡張薬、鎮咳薬、去痰薬、抗コリン薬、
カフェイン類、ビタミン類、生薬類、制酸薬等の薬剤を
適宜に配合することができる。In order to use the composition for treating a cold syndrome of the present invention as a remedy for a cold syndrome, in addition to adding echinacea and an antipyretic analgesic, if necessary, an antihistamine drug, an anti-inflammatory enzyme drug, a bronchodilator drug Antitussives, expectorants, anticholinergics,
Drugs such as caffeine, vitamins, crude drugs, and antacids can be appropriately compounded.
【0015】前記抗ヒスタミン薬としては、ジフェンヒ
ドラミン、クロルフェニラミン、ジフェニルピラリン、
イソチペンジル、プロメタジン、アリメマジン、メキタ
ジン、ジフェテロール、トリペレナミン、トンジルアミ
ン、フェネタジン、メトラジン、シプロヘプタジン、カ
ルビノキサミン、クレマスチン等およびこれらの塩類が
挙げられ、これらの単独または2種以上を用いることが
できる。The antihistamines include diphenhydramine, chlorpheniramine, diphenylpyramine,
Isotipendyl, promethazine, alimemazine, mequitazine, dipheterol, tripelenamine, tondiamine, phenetazine, metrazine, cyproheptadine, carbinoxamine, clemastine, and the like, and salts thereof, and these salts can be used alone or in combination of two or more.
【0016】前記消炎酵素薬としては、セラペプター
ゼ、ブロメライン、プロクターゼ、プロナーゼ、セミア
ルカリプロティナーゼ、ストレプトキナーゼ、塩化リゾ
チームおよびその類縁物質等が挙げられ、これらの単独
または2種以上を用いることができる。Examples of the anti-inflammatory enzyme include serrapeptase, bromelain, proctase, pronase, semi-alkaline proteinase, streptokinase, lysozyme chloride and related substances, and these can be used alone or in combination of two or more.
【0017】前記気管支拡張薬としては、エピネフリ
ン、イソプロテレノール、オルシプレナリン、クロルプ
レナリン、トリメトキノール、サルブタモール、テルブ
タリン、ヘキソプレナリン、プロカテロール、ツロブテ
ロール、ピルブテロール、フェノテロール、ホルモテロ
ール、クレンブテロール、マブテロール、テオフィリ
ン、アミノフィリン、コリンテオフィリン、ジプロフィ
リン等が挙げられ、これらの単独または2種以上を用い
ることができる。The bronchodilators include epinephrine, isoproterenol, orciprenaline, chlorprenaline, trimethokinol, salbutamol, terbutaline, hexoprenaline, procaterol, tulobuterol, pirbuterol, fenoterol, formoterol, clenbuterol, mabuterol, theophylline, aminophylline, theophylline, aminophylline, aminophylline, theophylline, aminophylline, and theophylline. Choline theophylline, diprofylline and the like can be mentioned, and these can be used alone or in combination of two or more.
【0018】前記鎮咳薬としては、コデイン、ジヒドロ
コデイン、エフェドリン、ノスカピン、デキストロメト
ルファン、ジメモルファン、エプラジノン、ベンプロブ
ロペリン、チペピジン、クロぺラスチン、クロフェダノ
ール、ホミノベン、グアイフェネシン、カルベタペンタ
ン等およびこれらの塩類が挙げられ、これらの単独また
は2種以上を用いることができる。Examples of the antitussives include codeine, dihydrocodeine, ephedrine, noscapine, dextromethorphan, dimemorphan, epradinone, benproproperine, tipepidine, cloperastine, clofedanol, hominoben, guaifenesin, carbetapentane and the like. And these may be used alone or in combination of two or more.
【0019】前記去痰薬としては、ブロムヘキシン、N
−アセチル−L−システイン、L−メチルシステイン、
L−エチルシステイン、カルボシステイン、アンブロキ
ソール等およびこれらの塩類が挙げられ、これらの単独
または2種以上を用いることができる。The expectorants include bromhexine, N
-Acetyl-L-cysteine, L-methylcysteine,
Examples thereof include L-ethylcysteine, carbocysteine, ambroxol and the like, and salts thereof, and these may be used alone or in combination of two or more.
【0020】前記抗コリン薬としては、イプラトロピウ
ム、フルトロピウム、オキシトロピウム等が挙げられ、
これらの単独または2種以上を用いることができる。The anticholinergic agents include ipratropium, flutropium, oxitropium and the like.
These can be used alone or in combination of two or more.
【0021】前記カフェイン類としては、カフェインお
よび無水カフェインが挙げられる。The above-mentioned caffeine includes caffeine and anhydrous caffeine.
【0022】前記ビタミン類としては、ビタミンB1 、
ビタミンB2 、ビタミンC等およびこれらの誘導体なら
びにこれらの塩類が挙げられ、これらの単独または2種
以上を用いることができる。The vitamins include vitamin B 1 ,
Vitamin B 2 , vitamin C, and the like, and derivatives thereof, and salts thereof, may be used alone or in combination of two or more.
【0023】前記生薬としては、半夏、細辛、けい芥、
生姜、甘草、柴胡、桂皮(枝)、(紫)蘇葉、麻黄、芍
薬、五味子、黄ごん、川きゅう、地黄、黄連、桔梗、麦
門冬、連翹、辛夷、丁字、うい香、ユーカリ、ラベンダ
ー、薄荷等の生薬末およびそのエキス等が挙げられ、こ
れらの単独または2種以上を用いることができる。[0023] The crude drugs include midsummer, spicy, garbage,
Ginger, licorice, saiko, cinnamon bark (branch), (purple) soba, mako, shakuyaku, gomiko, yellow bon, river cucumber, ground yellow, yellow ren, bellflower, wheat gate winter, renchi, spicy, choji, uika , Eucalyptus, lavender, herbal powders such as light loads, extracts thereof, and the like, and these can be used alone or in combination of two or more.
【0024】前記制酸薬としては、炭酸水粗ナトリウ
ム、炭酸カルシウム、酸化マグネシウム、乾燥水酸化ア
ルミニウムゲル、水酸化マグネシウム等が挙げられ、こ
れらの単独または2種以上を用いることができる。Examples of the antacid include crude sodium carbonate, calcium carbonate, magnesium oxide, dried aluminum hydroxide gel, magnesium hydroxide and the like, and these can be used alone or in combination of two or more.
【0025】なお、これらの成分は単独または相互に混
合して用いることができ、通常は医薬品製造指針(19
95年版・薬業時報社)に収載されている風邪薬等の基
準に準拠して配合される。These components can be used alone or in admixture with each other.
It is compounded in accordance with the standards for cold medicines and the like listed in the 1995 edition of Pharmaceutical Times.
【0026】本発明の風邪症候群治療用組成物は、上記
の成分を配合することにより総合感冒薬、解熱鎮痛薬、
鎮咳去痰薬、鼻炎用薬、感冒予防薬、免疫賦活薬、健康
食品等幅広い形態で用いることができる。The composition for treating a cold syndrome of the present invention comprises a general cold remedy, an antipyretic analgesic,
It can be used in a wide variety of forms such as antitussive expectorants, rhinitis drugs, cold preventives, immunostimulants and health foods.
【0027】本発明の風邪症候群治療用組成物における
前記エキナケアと解熱鎮痛薬の配合比は、エキナケア1
重量部に対し解熱鎮痛薬0.1〜50重量部、好ましく
は1〜30重量部がよい。前記配合比が上限を超えると
エキナケアの添加による服用感の改善効果が得られず、
下限未満ではエキナケアの添加量に見合う服用感の改善
効果が得られずいずれも好ましくない。とくに、エキナ
ケア1重量部に対する解熱鎮痛薬の前記配合比は、アセ
トアミノフェンでは0.3〜50重量部、イブプロフェ
ンでは0.1〜50重量部、エテンザミドでは0.2〜
50重量部およびイソプロピルアンチピリンでは0.1
〜50重量部が好ましい。In the composition for treating a cold syndrome of the present invention, the mixing ratio of the above-mentioned echinacea to the antipyretic analgesic is as follows.
The antipyretic analgesic is preferably 0.1 to 50 parts by weight, more preferably 1 to 30 parts by weight based on parts by weight. If the compounding ratio exceeds the upper limit, the effect of improving the feeling of taking by adding echinacea cannot be obtained,
If the amount is less than the lower limit, the effect of improving the feeling of ingestion corresponding to the added amount of echinacea cannot be obtained, and neither is preferable. In particular, the compounding ratio of the antipyretic analgesic to 1 part by weight of echinacea is 0.3 to 50 parts by weight for acetaminophen, 0.1 to 50 parts by weight for ibuprofen, and 0.2 to 50 parts by weight for etenzamide.
0.1 for 50 parts by weight and isopropylantipyrine
~ 50 parts by weight are preferred.
【0028】本発明の風邪症候群治療剤における前記エ
キナケアの有効量は、健康成人で一日25mg〜100
0mg(原生薬換算量1g〜40g)であり、好ましく
は50mg〜750mg(原生薬換算量2g〜30g)
がよい。The effective amount of the echinacea in the therapeutic agent for cold syndrome of the present invention is 25 mg to 100 mg / day for healthy adults.
0 mg (equivalent amount of crude drug 1 g to 40 g), preferably 50 mg to 750 mg (equivalent amount of crude drug 2 g to 30 g)
Is good.
【0029】また、本発明の風邪症候群治療剤における
前記解熱鎮痛薬の有効量は、健康成人で一日100mg
〜1200mgであり、好ましくは150mg〜900
mgがよい。The effective amount of the antipyretic analgesic in the therapeutic agent for cold syndrome of the present invention is 100 mg / day for healthy adults.
~ 1200 mg, preferably 150 mg ~ 900
mg is better.
【0030】本発明の風邪症候群治療用組成物は経口投
与用製剤として、常法により調製することができる。本
発明の風邪症候群治療用組成物を固形製剤とするには、
適当な添加剤、例えば、乳糖、ショ糖、マンニット、ト
ウモロコシデンプン、合成もしくは天然ガム、結晶セル
ロース等の賦形剤、デンプン、セルロース誘導体、アラ
ビアゴム、ゼラチン、ポリビニルピロリドン等の結合
剤、カルボシキメチルセルロースカルシウム、カルボシ
キメチルセルロースナトリウム、デンプン、コーンスタ
ーチ、アルギン酸ナトリウム等の崩壊剤、タルク、ステ
アリン酸マグネシウム、ステアリン酸ナトリウム等の滑
沢剤、炭酸カルシウム、炭酸ナトリウム、リン酸カルシ
ウム、リン酸ナトリウム等の充填剤または希釈剤等と適
宜混合して、錠剤、散剤(粉末)、丸剤、および顆粒剤
等にすることができる。また、硬質または軟質のゼラチ
ンカプセル等を用いてカプセル剤としてもよい。これら
の固型製剤には、ヒドロキシプロピルメチルセルロース
フタレート、ヒドロキシプロピルメチルセルロースアセ
テートスクシネート、セルロースアセテートフタレー
ト、メタアクリレートコポリマー等の被覆用基剤を用い
て腸溶性被覆を施してもよい。The composition for treating a cold syndrome of the present invention can be prepared by a conventional method as a preparation for oral administration. To make the composition for treating a cold syndrome of the present invention into a solid preparation,
Suitable additives, for example, excipients such as lactose, sucrose, mannitol, corn starch, synthetic or natural gum, crystalline cellulose, binders such as starch, cellulose derivatives, gum arabic, gelatin, polyvinylpyrrolidone, carboxy Disintegrants such as methylcellulose calcium, sodium carboxymethylcellulose, starch, corn starch, sodium alginate, lubricants such as talc, magnesium stearate, sodium stearate, fillers such as calcium carbonate, sodium carbonate, calcium phosphate, sodium phosphate or Tablets, powders (powder), pills, granules and the like can be appropriately mixed with a diluent and the like. Further, capsules may be prepared using hard or soft gelatin capsules or the like. These solid preparations may be provided with an enteric coating using a coating base such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, methacrylate copolymer and the like.
【0031】本発明の風邪症候群治療用組成物を液状製
剤とするには、精製水等の一般的に用いられる不活性希
釈剤に溶解して、必要に応じて、この溶液に浸潤剤、乳
化剤、分散助剤、界面活性剤等の溶解補助剤、保存剤、
香料、色素、甘味剤・嬌味剤、着色剤等を適宜添加する
ことにより、シロップ剤、エリキシル剤、内服液剤等と
することができる。In order to make the composition for treating cold syndrome of the present invention into a liquid preparation, it is dissolved in a generally used inert diluent such as purified water and the like, and if necessary, an infiltrant or an emulsifier is added to this solution. , Dispersing aids, dissolution aids such as surfactants, preservatives,
A syrup, an elixir, a liquid for internal use, and the like can be prepared by appropriately adding a flavor, a pigment, a sweetening agent / flavoring agent, a coloring agent, and the like.
【0032】本発明の風邪症候群治療用組成物を薬剤と
して投与する場合には、通常成人に対して1日当たり有
効成分として300〜1500mgを、1回ないし数回
に分けて経口投与することができる。この投与量は年
齢、体重、病状により適宜増減することができる。When the composition for treating a cold syndrome of the present invention is administered as a drug, it is usually possible to orally administer 300 to 1500 mg of the active ingredient per day to an adult in one or several divided doses. . This dose can be appropriately adjusted depending on the age, weight, and medical condition.
【0033】[0033]
【実施例】以下に、本発明の風邪症候群治療用組成物を
実施例をもってさらに詳細に説明するが、本発明はこれ
らの実施例に限定されるものではない。EXAMPLES Hereinafter, the composition for treating a cold syndrome of the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
【0034】(実施例1) アセトアミノフェン 900g リン酸ジヒドロコデイン 24g 塩酸メチルエフェドリン 60g マレイン酸クロルフェニラミン 6g エキナケア軟エキス 24g グアイフェネシン 125g 無水カフェイン 50g 乳糖 275g 低置換度ヒドロキシプロピルセルロース 275g ステアリン酸マグネシウム 35g 硬化ヒマシ油 26g 上記処方で各成分を各分量ずつ秤量し均一に混合した
後、得られた混合粉末を直打法により1錠重量300m
gになるように打錠し、錠剤6000個を得た。Example 1 Acetaminophen 900 g Dihydrocodeine phosphate 24 g Methylephedrine hydrochloride 60 g Chlorpheniramine maleate 6 g Echinacea soft extract 24 g Guaifenesin 125 g Anhydrous caffeine 50 g Lactose 275 g Low-substituted hydroxypropylcellulose 275 g Magnesium stearate 35 g Hardened Castor oil 26 g After weighing and uniformly mixing each component in the above-mentioned formulation, the obtained mixed powder was weighed 300 m / tablet by a direct compression method.
g to obtain 6000 tablets.
【0035】[実施例2] アセトアミノフェン 900g リン酸コデイン 18g 塩酸メチルエフェドリン 60g マレイン酸カルビノキサミン 12g エキナケア軟エキス 24g グアイフェネシン 125g 無水カフェイン 50g 乳糖 275g 低置換度ヒドロキシプロピルセルロース 275g ステアリン酸マグネシウム 32g 硬化ヒマシ油 29g 上記処方で各成分を各分量ずつ秤量し均一に混合した
後、得られた混合粉末を直打法により1錠重量300m
gになるように打錠し、錠剤6000個を得た。Example 2 Acetaminophen 900 g Codeine phosphate 18 g Methylephedrine hydrochloride 60 g Carbinoxamine maleate 12 g Echinacea soft extract 24 g Guaifenesin 125 g Anhydrous caffeine 50 g Lactose 275 g Low-substituted hydroxypropyl cellulose 275 g Magnesium stearate 32 g Hardened castor oil 29 g After weighing and uniformly mixing each component in the above formulation, the obtained mixed powder was weighed 300 m / tablet by a direct compression method.
g to obtain 6000 tablets.
【0036】[実施例 3] イブプロフェン 450g リン酸ベンプロペリン 30g 塩酸メチルエフェドリン 60g マレイン酸カルビノキサミン 12g エキナケア軟エキス 24g グアイフェネシン 125g 乳糖 374g 低置換度ヒドロキシプロピルセルロース 350g ステアリン酸マグネシウム 40g 硬化ヒマシ油 35g 上記処方で各成分を各分量ずつ秤量し均一に混合した
後、得られた混合粉末を直打法により1錠重量300m
gになるように打錠し、錠剤5000個を得た。Example 3 Ibuprofen 450 g Benproperin phosphate 30 g Methylephedrine hydrochloride 60 g Carbinoxamine maleate 12 g Echinacea soft extract 24 g Guaifenesin 125 g Lactose 374 g Low-substituted hydroxypropyl cellulose 350 g Magnesium stearate 40 g Hardened castor oil 35 g each of the above castor oil Are weighed and mixed uniformly, and the obtained mixed powder is weighed 300 m / tablet by a direct compression method.
g to obtain 5000 tablets.
【0037】(服用感比較試験)本発明の風邪症候群治
療用組成物の服用感を、盲検試験により官能評価した。(Comparative Test for Taking Feeling) The feeling of taking the composition for treating a cold syndrome of the present invention was sensory evaluated by a blind test.
【0038】表1に示した処方により、本発明の風邪症
候群治療用組成物(被験薬1、2)ならびにエキナケア
軟エキス単体(対照薬1)、アセトアミノフェン単体
(対照薬2)およびイブプロフェン単体(対照薬3)を
それぞれ粉末剤として調整した。エキナケアはNatt
ermann社(ドイツ)製・原生薬換算量3.0gを
用いた。被験薬1、2及び対照薬1〜3を風邪に罹患し
た者20名に服用させ、各薬剤の服用感を評価した。な
お、評価は「A:大変飲みやすい」、「B:飲みやす
い」、「C:どちらともいえない」および「D:飲みに
くい」の4段階とし、B以上の評価人数で比較した。結
果を表2に示す。According to the formulations shown in Table 1, the composition for treating cold syndrome of the present invention (test drugs 1 and 2), echinacea soft extract alone (control drug 1), acetaminophen alone (control drug 2) and ibuprofen alone (Control 3) were each prepared as a powder. Echinacea is Natt
ermann (Germany), 3.0 g of crude drug equivalent was used. The test drugs 1 and 2 and the control drugs 1 to 3 were taken by 20 people suffering from a cold, and the feeling of taking each drug was evaluated. In addition, evaluation was made into four grades of "A: very easy to drink", "B: easy to drink", "C: Neither can be said", and "D: difficult to drink", and it compared with the evaluation number of B or more. Table 2 shows the results.
【0039】[0039]
【表1】 [Table 1]
【0040】[0040]
【表2】 [Table 2]
【0041】表2の結果から明らかなように、本発明の
風邪症候群治療用組成物は、エキナケアおよび解熱鎮痛
剤を単独で服用した場合に比べて、著しく服用感が改善
されることがわかる。As is evident from the results in Table 2, it can be seen that the composition for treating a cold syndrome of the present invention significantly improves the feeling of taking as compared with the case where echinacea and an antipyretic analgesic are taken alone.
【0042】[0042]
【発明の効果】本発明の風邪症候群治療用組成物は、エ
キナケアおよび解熱鎮痛薬を配合してなるので、有効量
の解熱鎮痛剤を含有しつつも服用感に優れ、コンプライ
アンスが改善された風邪症候群治療剤を得ることができ
る。EFFECT OF THE INVENTION Since the composition for the treatment of cold syndrome of the present invention comprises an echinacea and an antipyretic analgesic, it is excellent in feeling of taking while having an effective amount of an antipyretic analgesic and has improved compliance. An agent for treating a syndrome can be obtained.
【0043】さらに、本発明の風邪症候群治療用組成物
は、エキナケアおよび解熱鎮痛薬を配合してなるので、
風邪の代表的症候群である発熱、頭痛、筋肉痛、咽頭
炎、悪寒等の軽減に効果があるほか、免疫能の回復によ
る風邪の諸症状の改善や二次感染の防止にも極めて有効
である。Further, the composition for treating a cold syndrome of the present invention comprises echinacea and an antipyretic analgesic.
It is effective in alleviating fever, headache, myalgia, pharyngitis, chills, etc., which are typical syndromes of colds, and is also extremely effective in improving various symptoms of colds by preventing immunity and preventing secondary infection. .
【0044】また、本発明の風邪症候群治療用組成物
は、さらに、抗ヒスタミン薬、消炎酵素薬、気管支拡張
薬、鎮咳薬、去痰薬、抗コリン薬、カフェイン類、ビタ
ミン類、生薬類および制酸薬からなる群より選ばれた少
なくとも1種の薬剤を配合してなるので、風邪の諸症状
に合わせた処方薬や感冒薬とすることができ、各種の風
邪症候群治療剤として有用である。The composition for treating a cold syndrome of the present invention further comprises an antihistamine, an anti-inflammatory enzyme, a bronchodilator, an antitussive, an expectorant, an anticholinergic, a caffeine, a vitamin, a crude drug and Since it contains at least one drug selected from the group consisting of antacids, it can be used as a prescription drug or cold medicine for various symptoms of cold, and is useful as a therapeutic agent for various cold syndromes .
Claims (3)
る風邪症候群治療用組成物。1. A composition for treating a cold syndrome comprising an echinacea and an antipyretic analgesic.
熱鎮痛薬0.1〜50重量部である請求項1記載の風邪
症候群治療用組成物。2. The composition for treating a cold syndrome according to claim 1, wherein the compounding ratio is 0.1 to 50 parts by weight of the antipyretic analgesic to 1 part by weight of echinacea.
イブプロフェン、エテンザミドおよびイソプロピルアン
チピリンからなる群より選ばれた少なくとも1種である
請求項1または2記載の風邪症候群治療用組成物。3. The antipyretic analgesic, acetaminophen,
The composition for treating a cold syndrome according to claim 1 or 2, wherein the composition is at least one selected from the group consisting of ibuprofen, etensamide and isopropylantipyrine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9107849A JPH10298088A (en) | 1997-04-24 | 1997-04-24 | Composition for curing cold syndrome improved in feeling when taking the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9107849A JPH10298088A (en) | 1997-04-24 | 1997-04-24 | Composition for curing cold syndrome improved in feeling when taking the same |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10298088A true JPH10298088A (en) | 1998-11-10 |
Family
ID=14469627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9107849A Withdrawn JPH10298088A (en) | 1997-04-24 | 1997-04-24 | Composition for curing cold syndrome improved in feeling when taking the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH10298088A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787164B2 (en) * | 2000-02-23 | 2004-09-07 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
-
1997
- 1997-04-24 JP JP9107849A patent/JPH10298088A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787164B2 (en) * | 2000-02-23 | 2004-09-07 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4365106B2 (en) | Pharmaceutical combination | |
WO2005117895A2 (en) | Compositions comprising meloxicam | |
JP2001199882A (en) | Composition for cold and rhinitis | |
JPH06287144A (en) | Pharmaceutical preparation for common cold | |
WO2021109511A1 (en) | Anti-fatigue composition and preparation method therefor | |
JPH1045595A (en) | Antitussive | |
JP3800437B2 (en) | Solution with reduced bitterness | |
JP2001097856A (en) | Antitussive | |
JP4787499B2 (en) | Pharmaceutical composition | |
JPH10298088A (en) | Composition for curing cold syndrome improved in feeling when taking the same | |
Hanson | Cough mixtures-an overview | |
JPH083066A (en) | Therapeutic drug for cold | |
JPH0656677A (en) | Antacid composition | |
JP2000273051A (en) | Liquid preparation whose bitter taste is masked | |
JP4710240B2 (en) | Pharmaceutical composition | |
JP3987501B2 (en) | Pharmaceutical composition | |
JP2005289906A (en) | Medicinal composition | |
HUT64216A (en) | Process for producing cough diminishing medical preparative containing dextrometorphane | |
JPH1072349A (en) | Cough medicine | |
JPS6256435A (en) | Coronary vasodilator | |
JPH11302189A (en) | Composition for cold | |
KR100208969B1 (en) | Anti-ulcers drug containing extract from chap-rice | |
JP2004210800A (en) | Antitussive | |
JPH1045577A (en) | Antitussive agent for cold | |
JP2001010966A (en) | Composition for treating cold syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20040706 |